MET heads into its August 5 earnings report with one of the cleanest analyst upgrade cycles in the insurance sector this summer — ten firms lifting price targets in under three weeks, and the stock still trading below the Street's consensus.
The analyst story here is unusually coordinated. JP Morgan raised its target to $106 on Tuesday, keeping an Overweight rating. TD Cowen followed Wednesday, lifting to $105 from $87 — an 21% increase — while holding its Buy. Those moves cap a run that started in early July: Morgan Stanley, UBS, Jefferies, Mizuho, Wells Fargo, Keefe Bruyette, and Evercore ISI all nudged targets higher over the same window, with not one downgrade or rating cut in the mix. The mean consensus price target now sits at $96.63, while MET closed Tuesday at $93.37 — implying around 3.5% to the Street's average, and roughly 13.5% to JP Morgan's more bullish $106. The coordinated target-lift pattern looks less like fresh conviction and more like the Street catching up with a stock that has already run 9% in a month.
Positioning in the lending market offers no resistance to that rally. Borrow availability is effectively unlimited — the lending pool is almost entirely untapped, with availability running at the 52-week high. Short interest is a modest 2.1% of the free float, and it has been drifting lower, down nearly 5% over the past month. Cost to borrow is negligible at 0.48%. For context, back in mid-June availability was far tighter, with utilization running closer to 3%; that pressure has evaporated completely through July. There is no squeeze dynamic to complicate the thesis, and no meaningful short-side pushback evident in the borrow market.
Options positioning is broadly neutral. The put/call ratio is running at 1.27, barely a fraction of a standard deviation above its 20-day average of 1.25. The 52-week range spans 1.07 to 1.81, so the current reading is unremarkable — options traders are not leaning defensively into the August print the way they might if the setup felt uncertain. The recent history offers a mild note of caution though: MET has fallen on the day of each of its last three earnings releases, with declines ranging from roughly 1.4% to 2.6%. Five-day reactions have been mixed, with one mild recovery and two extended dips. The pattern is modest in absolute terms, but it's a consistent one.
The institutional picture is stable. BlackRock added nearly 1.4 million shares to its roughly 8% stake through June, and T. Rowe Price built by 2.5 million shares to hold 3.5% of the company. Dodge & Cox, already one of the largest holders at close to 8%, was essentially flat. The MetLife Policyholder Trust, the single largest holder at 16%, trimmed slightly. The overall picture is of large passive and active managers slowly adding — no dramatic repositioning either way ahead of the print.
On valuation, the stock trades at a trailing P/E of 8.9 and a price-to-book of 1.93, both ticking higher with the month's rally. The forward EPS momentum factor ranks in the 90th percentile — a notable score suggesting analysts expect meaningful earnings growth over the next twelve months. The ORTEX short score of 35 is subdued, consistent with the low short interest and loose borrow. What to watch on August 5 is whether the Q2 print gives the Street a reason to sustain those freshly lifted targets, or whether the stock's familiar post-earnings softness reasserts itself in the face of what is now a more fully priced consensus.
See the live data behind this article on ORTEX.
Open MET on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
